Shoreline Biosciences, Inc., a San Diego, CA-based biotechnology company, completed a $43M funding round.
The round was led by Boxer Capital, with participation from BVF Partners L.P., Commodore Capital, Cormorant Capital, Janus Henderson Investors, Logos Capital, Kite, a Gilead company, and Wedbush Healthcare Partners, in addition to Stork Capital, and other investors. In connection with the financing, Christopher Fuglesang, Ph.D., J.D. from Boxer Capital, joined the Shoreline Board of Directors.
Co-founded by cell therapy expert Dan Kaufman, M.D., Ph.D., and biotech veterans Steven Holtzman, William Sandborn, M.D. and Kleanthis G. Xanthopoulos, Ph.D., Shoreline Biosciences is developing intelligently designed allogeneic off-the-shelf, standardized and targeted natural killer (NK) and Macrophage cellular immunotherapies derived from induced pluripotent stem cells (iPSC) for cancer and other serious diseases.
The company intends to use the funds to accelerate the advancement of its proprietary iPSC platform focused on developing next generation NK cell and macrophage-cell therapies, while also supporting research efforts to create potent and persistent NK cell-specific Chimeric Antigen Receptors (CARs), switchable CAR-NK cell engagers and macrophage-specific CARs. In addition, Shoreline has entered into a strategic relationship with the Advanced Cell Therapy Laboratory of UC San Diego to secure GMP manufacturing of its cell therapy products.
FinSMEs
08/04/2021